Wed. 15 May 2024, 8:46am ET
Benzinga
News
- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).